These results indicate that a rapid progression in SMM occurs through the blockade of PD-1+CD8+ T lymphocytes by the tumor cells irrespectively of Treg cells, and suggest that SMM patients at high risk of progression may benefit from anti-PD-1 therapy. This evidence concerns the gene CD8A and neoplasm.